Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 15/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL17555192 | 0.99 | CCR2 (0.80) | CCR2LMNAPTGS1CCR5P2RX1 | |
| Hydrochloric Acid SCHEMBL313256 | 0.99 | CCR2 (0.80) | CCR2LMNAPTGS1CCR5P2RX1 | |
| SCHEMBL13148229 | 0.90 | CCR2 (1.00) | CCR2CCR5 | |
| Hydrochloric Acid SCHEMBL313759 | 0.89 | CCR2 (0.98) | CCR2CCR5 | |
| Iodide SCHEMBL17555140 | 0.89 | CCR2 (0.98) | CCR2CCR5 | |
| SCHEMBL13148091 | 0.88 | CCR2 (0.64) | CCR2LMNA | |
| Hydrochloric Acid SCHEMBL313403 | 0.87 | CCR2 (0.63) | CCR2LMNA | |
| Iodide SCHEMBL17555155 | 0.87 | CCR2 (0.63) | CCR2LMNA | |
| SCHEMBL313432 | 0.84 | CCR2 (0.81) | CCR2CCR5 | |
| Iodide SCHEMBL3075475 | 0.83 | CCR2 (0.79) | CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765803-B1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-8168829-B2 | Synthesis of quaternary salt compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-01 | — | — | US | disclosed |
| US-8093428-B2 | Synthesis of quaternary salt compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-10 | — | — | US | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090112003-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090112004-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090112003-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | CCR2, CCR1, CCL11 | CCR2 1/4885LMNA 4581/4885PTGS1 1151/4885 |
| US-20090112004-A1 | SYNTHESIS OF QUATERNARY SALT COMPOUNDS | CCR2, CCR1, CCL11 | CCR2 1/4885LMNA 4581/4885PTGS1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.